SAN DIEGO, Aug. 4, 2011 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the
Company's Chief Executive Officer, Brian M.
Culley, will present at the 31st Annual Canaccord Genuity
Growth Conference on Thursday August 11th,
2011, at 3:30 pm Eastern time,
in the Vancouver Room at the Intercontinental Hotel in Boston.
Interested parties can access a live audio webcast and slide
presentation on the ADVENTRX Pharmaceuticals web site at
www.adventrx.com. An archived presentation will be available on the
web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a specialty pharmaceutical company
focused on acquiring, developing and commercializing proprietary
product candidates. The Company's current lead product candidates
are Exelbine and ANX-514, novel emulsion formulations of currently
marketed chemotherapy drugs, and ANX-188, a novel, purified,
rheologic and antithrombotic compound initially being developed as
a first-in-class treatment for pediatric patients with sickle cell
disease in acute crisis. More information can be found on the
Company's web site at www.adventrx.com.
SOURCE ADVENTRX Pharmaceuticals, Inc.